Search Results | NIH

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Search Results 2561 – 2580 of 3236

Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/management-infants-utero-intrapartum-breastfeeding-hiv-exposure

Human Papillomavirus Disease

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/human

Appendix C: Antiretroviral Medications That Can Be Switched Temporarily If Unable to Access Certain Formulations

https://clinicalinfo.hiv.gov/guidelines/guidance-hiv-disasters/appendix-antiretroviral-medications-switched-temporarily

Maraviroc (Selzentry, MVC)

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-entry-attachment-inhibitors-maraviroc-selzentry

Disseminated Mycobacterium avium Complex Disease

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/disseminated

Mycobacterium avium Complex Disease

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/mycobacterium-avium-complex

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/fosamprenavir

Varicella-Zoster Virus Disease

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/varicella-zoster-virus

Preventing HIV Transmission During Infant Feeding

https://clinicalinfo.hiv.gov/guidelines/perinatal/preventing-transmission-infant-feeding

Appendix D. Financial Disclosures

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/appendix-financial-disclosures

Appendix A: Sample Short Intake Form for People With HIV Who Are Seeking Care

https://clinicalinfo.hiv.gov/guidelines/guidance-hiv-disasters/appendix-sample-short-intake-form

Nevirapine (Viramune, NVP)

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-nnrtis-nevirapine-viramune

Table 3. Indications for Discontinuing and Restarting Primary and Secondary Prophylaxis (or Chronic Maintenance Therapy) for Selected Opportunistic Infections in Adults and Adolescents with HIV

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/indications-discontinuing-and

Special Populations: Early (Acute and Recent) HIV Infection

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/special-populations-early-acute-recent-hiv-infection

Antiretroviral Pregnancy Registry

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-pregnancy-registry

Rilpivirine (Edurant, RPV)

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-nnrtis-rilpivirine-edurant

Lipodystrophies and Weight Gain

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/lipodystrophies-and-weight-gain

Financial Disclosure

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/financial-disclosure

Tenofovir Alafenamide (Vemlidy, TAF)

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-nrtis-tenofovir-alafenamide-vemlidy

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/syphilis